TGFB1 and neoplasm: Patients with primary tumor itself may respond to anti-TGFβ therapies, but patients with cancer-associated MSCs may benefit from a prophylactic or targeted treatment with TGFβ inhibitor to revert activated tumor-associated MSCs to a naïve state.